Antibody fragments as nanoparticle targeting ligands: a step in the right direction

Richards, Daniel A.; Maruani, Antoine; Chudasama, Vijay

doi:10.1039/c6sc02403c

Cited by 240 publications

(147 citation statements)

References 148 publications

Supporting

Mentioning

146

Contrasting

Order By: Relevance

“…Encapsulation/conjugation of chemotherapeutic agents inside these vehicles protects them from degradation by physiological processes after administration, while also facilitating their transport across the cellular membrane. Additionally, their high surface functionality can be exploited by attaching specific targeting moieties (antibodies, peptides, or glycosylated moieties). These properties can lead to higher therapeutic efficacy, tumor selectivity, and reduced side effects for nanoparticle drug delivery vectors, in comparison to their molecular drug counterparts …”

Section: Introductionmentioning

confidence: 99%

RAFT Emulsion Polymerization as a Platform to Generate Well‐Defined Biocompatible Latex Nanoparticles

Gurnani

Sanchez‐Cano

Abraham

et al. 2018

Macromolecular Bioscience

View full text Add to dashboard Cite

Current approaches to generate core-shell nanoparticles for biomedical applications are limited by factors such as synthetic scalability and circulatory desorption of cytotoxic surfactants. Developments in controlled radical polymerization, particularly in dispersed states, represent a promising method of overcoming these challenges. In this work, well-defined PEGylated nanoparticles are synthesized using reversible addition fragmentation chain transfer emulsion polymerization to control particle size and surface composition and were further characterized with light scattering, electron microscopy, and size exclusion chromatography. Importantly, the nanoparticles are found to be tolerated both in vitro and in vivo, without the need for any purification after particle synthesis. Pharmacokinetic and biodistribution studies in mice, following intraperitoneal injection of the nanoparticles, reveal a long (>76 h) circulation time and accumulation in the liver.

show abstract

Section: Introductionmentioning

confidence: 99%

RAFT Emulsion Polymerization as a Platform to Generate Well‐Defined Biocompatible Latex Nanoparticles

Gurnani

Sanchez‐Cano

Abraham

et al. 2018

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…The complex structures and post‐translational modifications of full antibodies constrain their wide application . Antibody‐derived fragments can alleviate the problems and expand the potential of antibody‐mediated drug delivery.…”

Section: Positive Targetingmentioning

confidence: 99%

Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines

Qin

Zhang

2018

Small

109

View full text Add to dashboard Cite

Efficacy and safety of chemotherapeutic drugs constitute two major criteria in tumor chemotherapy. Nanomedicines with tumor-targeted properties hold great promise for improving the efficacy and safety. To design targeted nanomedicines, the pathological characteristics of tumors are extensively and deeply excavated. Here, the rationale, principles, and advantages of exploiting these pathological characteristics to develop targeted nanoplatforms for tumor chemotherapy are discussed. Homotypic targeting with the ability of self-recognition to source tumors is reviewed individually. In the meanwhile, the limitations and perspective of these targeted nanomedicines are also discussed.

show abstract

“…Fabs consist of a single constant and variable domain form each heavy and light chains. Compared to conventional IgG antibodies (~150kDa), single-chain variable fragment (scFv) antibodies (~27kDa) and antigen-binding (Fab) fragments (~57kDa) are smaller in molecular size and weight [282,285,286]. …”

Section: Approaches To Alleviate the Np-associated Adverse Effectsmentioning

confidence: 99%

Unintended effects of drug carriers: Big issues of small particles

Parhiz

Khoshnejad

Myerson

et al. 2018

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Humoral and cellular host defense mechanisms including diverse phagocytes, leukocytes, and immune cells have evolved over millions of years to protect the body from microbes and other external and internal threats. These policing forces recognize engineered sub-micron drug delivery systems (DDS) as such a threat, and react accordingly. This leads to impediment of the therapeutic action, extensively studied and discussed in the literature. Here, we focus on side effects of DDS interactions with host defenses. We argue that for nanomedicine to reach its clinical potential, the field must redouble its efforts in understanding the interaction between drug delivery systems and the host defenses, so that we can engineer safer interventions with the greatest potential for clinical success.

show abstract

Antibody fragments as nanoparticle targeting ligands: a step in the right direction

Abstract: Recent advances in nanomedicine have shown that dramatic improvements in nanoparticle therapeutics and diagnostics can be achieved through the use of disease specific targeting ligands.

Cited by 240 publications

References 148 publications

RAFT Emulsion Polymerization as a Platform to Generate Well‐Defined Biocompatible Latex Nanoparticles

RAFT Emulsion Polymerization as a Platform to Generate Well‐Defined Biocompatible Latex Nanoparticles

Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines

Unintended effects of drug carriers: Big issues of small particles

Contact Info

Product

Resources

About